image_alt_text
3

Jeffrey L. Cleland, Ph.D.

AIMBE College of Fellows Class of 2016
For outstanding contributions to the development and commercialization of protein and antibody-based medicines and leadership in the biotechnology industry

New PET Tracer May Better Capture Brain Inflammation in ALS

Via ALS News Today | October 11, 2021

An imaging agent developed by Ashvattha Therapeutics can accurately detect brain inflammation caused by microglia, immune cells that play a key role in neurological diseases such as amyotrophic lateral sclerosis (ALS), a mouse study reported.

The company is planning to initiate a Phase 1/2 clinical trial in ALS patients next year, using its PET tracer to help determine the efficacy of OP-101, a candidate therapy to prevent neuroinflammation by targeting microglia in the brain… Continue reading.

...

Jeffrey L. Cleland, Ph.D. To be Inducted into Medical and Biological Engineering Elite

Via AIMBE | January 20, 2016

WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Jeffrey L. Cleland, Ph.D., Interim CEO, GrayBug, Inc., , GrayBug, Inc., to its College of Fellows. Dr. Cleland was nominated, reviewed, and elected by peers and members of the College of Fellows For outstanding contributions to the development and commercialization of protein and antibody-based medicines and leadership in the biotechnology industry.

...